Dan Gooding

Dan Gooding is the Executive Director and co-founder of Nuformix Plc, a pharmaceutical development company focused on creating innovative therapies through cocrystal technology. He holds a PhD in Chemistry from Leeds University and has over 18 years of experience in commercialization and business development within the pharmaceutical industry.

Professional Background

Gooding began his career in commercial roles with companies specializing in pharmaceutical excipients, including FMC and Dow Corning. He later worked at Accelrys, where he was responsible for sales across the UK and Southern Europe, particularly in emerging sectors like nanotechnology and drug delivery. His experience includes leading successful licensing deals with major pharmaceutical companies such as Johnson & Johnson and AstraZeneca.12

At Nuformix, Gooding has been instrumental in advancing the company's drug development programs, particularly NXP001 and NXP002, which target high-value unmet medical needs. Under his leadership, Nuformix has pursued partnerships for further development of its products, focusing on repurposing known drugs to mitigate risks associated with new therapies.23

Current Role

As Executive Director, Gooding is actively involved in strategic planning and business development efforts aimed at securing licensing agreements and advancing clinical studies. His recent discussions have included updates on patent developments for Nuformix's lead programs, highlighting the company's ongoing commitment to innovation in the pharmaceutical sector.2

In summary, Dan Gooding's extensive background in pharmaceutical commercialization and his leadership at Nuformix position him as a key figure in the advancement of new therapeutic solutions.